Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference study of subcutaneous MK-3475A versus intravenous Keytruda in multiple solid tumors
2023-506017-22-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants who prefer MK-3475A subcutaneous administration. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
melanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506017-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506017-22-00.